Universität zu Köln

Kirn, Verena, Shi, Rong, Heublein, Sabine, Knabl, Julia, Guenthner-Biller, Margit, Andergassen, Ulrich, Fridrich, Claudius, Malter, Wolfram, Harder, Jan, Friese, Klaus, Mayr, Doris and Jeschke, Udo (2014). Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients. J. Cancer Res. Clin. Oncol., 140 (10). S. 1681 - 1688. NEW YORK: SPRINGER. ISSN 1432-1335

Full text not available from this repository.

Abstract

Ovarian carcinoma is the third most common gynecological cancer and only short recurrence-free survival and overall survival times are archived. The role of the estrogen receptor expression is well studied in breast cancer and breast cancer cell lines. Patients with positive estrogen receptor expression have a lower risk for recurrence and a better overall survival. Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma. A total of 75 patients were identified that were treated for ovarian carcinoma by debulking surgery and adjuvant standard chemotherapy. Isolation and bisulfite treatment of genomic DNA from serial sections of surgically resected ovarian carcinoma tissue was performed using commercially available kits. For the detection of methylated ESR1 promoter sequences, real-time methylation-specific PCR was used. Promoter methylation did not show a correlation between clinical-pathological data for all patients. However, within the subgroup of low-grade ovarian carcinoma patients and patients with an ovarian tumor of low malignant potential methylation of the ESR1 promoter inversely correlated with survival (p = 0.031). Although small numbers of ovarian carcinoma patients were analyzed, methylation status might be useful as a prognostic marker within the subgroup of low-grade ovarian carcinoma patients. Further studies should investigate a larger cohort and also address the use of demethylation agents with respect to improve patient's prognosis in this subgroup of ovarian carcinoma patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kirn, Verena UNSPECIFIED UNSPECIFIED UNSPECIFIED Shi, Rong UNSPECIFIED UNSPECIFIED UNSPECIFIED Heublein, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED Knabl, Julia UNSPECIFIED UNSPECIFIED UNSPECIFIED Guenthner-Biller, Margit UNSPECIFIED UNSPECIFIED UNSPECIFIED Andergassen, Ulrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Fridrich, Claudius UNSPECIFIED UNSPECIFIED UNSPECIFIED Malter, Wolfram UNSPECIFIED UNSPECIFIED UNSPECIFIED Harder, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Friese, Klaus UNSPECIFIED UNSPECIFIED UNSPECIFIED Mayr, Doris UNSPECIFIED UNSPECIFIED UNSPECIFIED Jeschke, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-427757
DOI:	10.1007/s00432-014-1729-9
Journal or Publication Title:	J. Cancer Res. Clin. Oncol.
Volume:	140
Number:	10
Page Range:	S. 1681 - 1688
Date:	2014
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1335
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CPG-ISLAND METHYLATION; GENE-EXPRESSION; CANCER; HYPERMETHYLATION; PATHOGENESIS; BIOMARKERS; MARKER Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42775